{"doi":"10.3389/fphys.2025.1597211","title":"Editorial: Physiology of human myopathies","abstract":"The study by Yang et al. (Yang et al. 2024) addresses the uncoupling between PKA-mediated phosphorylation of troponin I and muscle regulation due to cardiomyopathy-linked mutations in sarcomeric actin (ACTC gene) and troponin T (TNNT2 gene) (Marston and Pinto 2022). It also explores the ability of small molecules to restore coupling and normal heart function. Specifically, the authors investigated the effects of nutraceutical compounds -silybin B, resveratrol, and epigallocatechin-3-gallate (EGCG) -on restoring the heart's ability to relax during diastole (lusitropy) in two models of cardiomyopathy (Yang et al. 2024). These nutraceuticals were found to interact with cardiac troponin, restore the PKA-mediated modulation of myofilament Ca 2+sensitivity, thus improving diastolic function in hearts containing the ACTC-E99K and TNNT2-R92Q mutations. A strength of this study is its use of complementary experimental approaches, including in vitro (cell-based), in vivo (animal), and in silico (computational modeling) techniques. Molecular dynamics simulations revealed that silybin B, EGCG, and resveratrol restored the phosphorylation-induced change in troponin C helix A/B angle and interdomain angle to the levels observed in wild-type conditions in the presence of the TNNC1-G159D mutation. Previous studies have shown that resveratrol reduces oxidative stress, while EGCG has anti-inflammatory properties (Payne et al. 2023, Wei et al. 2023). However, the discovery by Yang et al. (2024) that these nutraceutical compounds restore lusitropy by interacting with troponin adds a novel dimension to their therapeutic potential. Recent clinical trials using nutraceuticals such as Lcarnitine, hawthorn and n-3 PUFA have shown improvements in functional parameters and quality of life in heart failure patients (Cicero et al. 2020). Further research on these compounds and their potential benefits for cardiac function may lead to novel treatment options for cardiomyopathy.The article by Creso et al. (Creso et al. 2024) investigated the molecular mechanisms underlying hypocontractility caused by the M8R tropomyosin (TPM1 gene) mutation, which has been associated with dilated cardiomyopathy in humans. Using both in silico (computational) and in vitro (experimental) models, the authors revealed that the TPM1-M8R mutation disrupts normal interactions between tropomyosin and actin-myosin filaments, leading to reduced cardiac muscle contraction efficiency (Creso et al. 2024). Previous studies have shown that the M8R mutation, located at the overlap junction of tropomyosin strands, decreases Ca 2+ -sensitivity and thin filament cooperativity, and weakens tropomyosin's ability to bind actin, perturbing thin filament regulatory function (Racca et al. 2020). In this study, the authors extended these results using a human tissue engineering approach as well as in silico modeling, circular dichroism (CD), actin cosedimentation, and in vitro gliding filament assays to provide mechanistic insight into how the mutation-induced molecular effects influence more physiologically relevant cardiac tissue function. The development of more efficient and cost-effective gene modification techniques, as presented in (Creso et al. 2024), suggests that these approaches may become useful therapeutic options for patients with severe cardiomyopathy caused by mutations in sarcomeric proteins.Pang et al (Pang et al. 2023) reviewed the role of the ubiquitin-proteasome pathway (UPP) in skeletal muscle atrophy, a condition characterized by the loss or deterioration of muscle mass and tissue due to an imbalance between protein synthesis and degradation. The UPP is a highly complex pathway present in all tissues, involving hundreds of different proteins that work together to remove damaged or unwanted proteins (Gilda and Gomes 2017). It functions by tagging target proteins with ubiquitin, marking them for degradation by the proteasome. Proteomic and other studies of various condit","journal":"Frontiers in Physiology","year":2025,"id":563813,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9582,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":328411,"name":"José R. Pinto","orcid":"0000-0001-9092-4976","position":1,"is_corresponding":false},{"id":354518,"name":"Danuta Szczesna‐Cordary","orcid":"0000-0002-8441-0722","position":2,"is_corresponding":false},{"id":266250,"name":"Aldrin V. Gomes","orcid":"0000-0002-9819-3036","position":0,"is_corresponding":true}],"reference_count":10,"raw_metadata":null,"created_at":"2026-07-19T02:56:17.117043Z","pmid":"40260204","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}